DERM Stock Summary and Trading Ideas (Journey Medical | NASDAQ:DERM)

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Journey Medical trades on the NASDAQ stock market under the symbol DERM.

As of December 11, 2025, DERM stock price climbed to $7.78 with 154,760 million shares trading.

DERM has a beta of -0.09, meaning it tends to be less sensitive to market movements. DERM has a correlation of 0.00 to the broad based SPY ETF.

DERM has a market cap of $211.12 million. This is considered a Small Cap stock.

Last quarter Journey Medical reported $18 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-761,250 and missed earnings estimates by -$.04.

In the last 3 years, DERM traded as high as $9.40 and as low as $1.02.

The top ETF exchange traded funds that DERM belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

DERM has outperformed the market in the last year with a return of +50.2%, while the SPY ETF gained +14.6%. In the last 3 month period, DERM beat the market returning +5.9%, while SPY returned +5.1%. However, in the most recent 2 weeks DERM has underperformed the stock market by returning -0.6%, while SPY returned +1.4%.

DERM support price is $7.42 and resistance is $7.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DERM shares will trade within this expected range on the day.